Agilent Technologies - Utilizing Fast HPLC Screening Methods for the Detection of Steroids
As the importance of steroids in the regulation of bioprocesses has increased so has the demand for fast screening methods for their detection. HPLC is a highly regarded analytical technique for pharmaceutical applications due to its unrivalled analytical validation characteristics; including accuracy, precision, limit of detection, specificity, linearity and range, and ruggedness.
The high throughput demands of quantitative steroid analysis require faster run times and as a result there has been a focus on the development of fast HPLC screening methods to detect steroids such as hydrocortisone, testosterone and progesterone. Recent developments in HPLC column technology, such as sub-2 μm totally porous and sub-3 μm superficially porous columns, have offered improvements in separation speed and performance through reduced analysis times and increased separation efficiency. It is these improvements in column technology which mean that fast HPLC screening for the detection of steroids can be achieved.
Selectivity is the most powerful tool to optimize separations in HPLC and can be manipulated to improve separations. As a result, the analysis of steroids can be dramatically improved by choosing the optimal HPLC column for the separation. Selectivity can be increased by changing the mobile phase composition, column temperature and the composition of stationary phase; for example, the short column length and high efficiency of Poroshell 120 HPLC columns provide fast HPLC analysis times and rapid equilibration leading to fast investigations of selectivity.
A key feature of Poroshell 120 columns is their superficially porous microparticulate column packing. Poroshell 120 particles have a 1.7 μm solid silica core with a 0.5 μm porous outer layer. This unique configuration delivers all the performance advantages of sub-2 μm particles with the backpressure of a sub-3 μm particle. With Poroshell 120 columns, it is possible to achieve 80–90% or more of the efficiency expected from a sub-2 μm Fast LC/UHPLC column — but at HPLC pressures (below 400 bar). This ability to perform fast separations at low pressures can dramatically enhance productivity by allowing more samples to be run in less time — even using existing HPLC systems. This allows laboratories to generate better chromatographic results quicker so they can increase their throughput of samples.
To read the full story and discover how you can achieve fast HPLC screening methods click here.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance